MAJDA ŠAHMAN-ZAIMOVIĆ

Curriculum Vitae

**Lični podaci :** Prezime : Šahman-Zaimović

 Ime : Majda

 Nacionalnost: Crna Gora

 Datum rođenja: 23.08.1965

 Adresa: Džordža Vašingtona 1-7-24 Podgorica

 Crna Gora

 E-mail majda.sahman@calims.me

**Edukacija :**

* Medicinski fakultet u Beogradu -1996
* Specijalizacija Pneumoftiziologije-Medicinski fakultet Beograd - 2002
* Magistarske studije- Medicinski fakultet Beograd - 2003

Magistarski rad: Značaj citoimunološke analize bronhoalveolarne lavaže u diferencijalnoj dijagnostici perifernih lezija pluća

* Specijalisticke studije : Menadžment javnog zdravstva -Medicinski fakultet Beograd- 2004-2006

Specijalisticki rad: Inovativne promjene na farmaceutskom tržištu-

-Organizacija i struktura Agencije za lijekove

* Doktorske studije-Medicinski fakultet Novi Sad-2010-2012

Doktorska disertacija: Odnos farmakoterapijske prakse i rezistencije kod vanbolničkih bakterijskih infekcija” oktobar 2012

Osnovne oblasti istraživanja Šahman Zaimović Majde su farmakologija i farmakoterapija. U ovim oblastima, ostvaruje saradnju sa referentnim inostranim laboratorijama, agencijama i institutima.

Majda Šahman Zaimović je publikovala naučne radova u cjelini i sažetake u domaćim i inostranim zbornicima naučnih radova.

Član je istraživačkog tima Centra za bioetičke studije za jugoistočnu Evropu –Unesko-katedra za bioetiku i presednik UO Centra za bioetičke studije u Crnoj Gori.

**Radno iskustvo**

* Medicinski fakultet-studijski program farmacija-nastavnik na Kliničkoj farmaciji-V godina i Farmakologiji I, treća godina-2015/2016 god.
* Agencija za lijekove i medicinska sredstva-zamjenik direktora -2009
* Ministarstvo zdravlja Crne Gore – savjetnik ministra za farmaceutsku politiku 2007-2009
* Ministarstvo zdravlja Crne Gore 2005- konsultant -Projekat Svetske Banke
* Specijalistička ordinacija za plućne bolesti Podgorica 2002-2005
* Ministarstvo zdravlja Republike Srbije2004-2005- saradnik na programima Svetske Banke
* Specijalna bolnica za plućne bolesti Brezovik 2001- 2002
* Klinički Centar Srbije Institut za plućne Beograd 1998-2001
* Ekspert Svetske banke na projektu razvoj farmaceutske politike-2005-2009
* Ekspert Svetske zdravstvene organizacije u oblasti ljekova-OD 2005
* Konsultant UNDP

BIBLIOGRAFSKI PODACI O STRUČNIM I NAUČNIM RADOVIMA:

Puni radovi:

1. **Majda Šahman Zaimović\*,** Saša Vukmirović, Nataša Tomić‡, Nebojša Stilinović†, Olga Horvat†, Ljiljana Tomić,:**|** "Relationship between outpatient antibiotic use and prevalence of bacterial infections in Montenegro".”Veza izmedju vanbolničke upotrebe antibiotika I prevalence bakterijskih infekcija u Crnoj Gori **“.**Vojnosanit Pregl 2017; January vol. 74(1): pp
2. **Majda Šahman Zaimovic**\*, Sabina Salihbegović Šahman, Eva Zver,:“Analysis of the funding sources of health systems in the ex-yugoslavia countries **".”Analiza izvora finansiranja zdravstvenih sistema zemalja u sastavu bivse Jugoslavije"** , Medicinski časopis Srpsko lekarsko društvo podružnica Kragujevac, 2018 vol. 52, issue2,...in press
3. Stilinović N, Vukmirović S, Milijašević B, Horvat O, **Sahman M**, Tomić Z, Šramka M, Sabova A. Lieky v domacich lekarničkach v Srbsku a na Slovensku: ich nebezpečie na zdravie uživatelov. Zdravotnictvo a socialna praca, 2008; 3(3-4): 15-21.
4. **Šahman M**, Drljević M. Strategija razvoja i organizacija Agencije za lijekove i medicinska sredstva Crne Gore. Pharmaca Iugoslavica, 2008; 43(3-4): 60-63.
5. Tomic Z, Milijasevic B, Sabo A, Lalosevic D, Jakovljevic V, Mikov M, **Sahman M**, Vasovic V. Diclofenac and ketoprofen liver toxicity in rat. Eur. J. Drug Metabol. Pharmacokinet., 2008; 33(4): 253-260.
6. Golocorbin-Kon S, Mikov M, Arafat M, Lepojevic Z, Mikov I, **Sahman-Zaimovic M,** Tomic Z. Cefotaxime pharmacokinetics after oral application in the form of 3α,7α-dihydroxy-12-keto-5β-cholanate micro vesicles in rat. Eur. J. Drug Metabol. Pharmacokinet., 2009; 34(1): 31-36.
7. Vukmirović S, Tomić Z, Sabo A, Milijašević B, **Šahman M**. Analiza vanbolničke upotrebe lekova ATC grupe A izdatih na recept na teret sredstava Republičkog fonda za zdravstvo Crne Gore u 2007. godini. Pharmaca Serbica, 2009;1 (1-2): 41-43.
8. Tomic Z, Mikov M, Sabo A, Milijasevic B, **Sahman M**, Andric V. Pharmacoepidemiology and pharmacoeconomic aspects of use of ACE inhibitors in Serbia compared with Montenegro in 2009. ISPOR 14th Annual European Congress, Madrid, Spain, 5-8 November, 2011. Value in Health. 2011; 14(7), A368.
9. Milijašević B, Tomić Z, Sabo A, Mikov M, **Šahman M**, Andrić V. Upotrebe ACE inhibitora u Srbiji u poređenju sa Crnom Gorom u 2009. godini. Simpozijum - III nedelja bolničke kliničke farmakologije. Srpsko lekarsko društvo Akademija medicinskih nauka, Beograd: 17-19 novembar, 2011. Apstract book:69-70
10. Tomić Z, Sabo A, Vukmirović S, **Šahman Zaimović M**, Horvat O, Milijašević B, Tomić N. Pharmacotherapy of urinary tract infections in the outpatient conditions. Kongres - V nedelja bolničke kliničke farmakologije. Srpsko lekarsko društvo Akademija medicinskih nauka, Beograd, 29. novembar – 1. decembar, 2013. Apstract book: 54-5
11. Mugosa S, Stankovic M, Turkovic N, **Sahman – Zaimovic M,** Besovic Z,Drljevic M. Pharmacovigilance – Imperative of Modern Medicine.Vojnosanit Pregl 2015; in press.
12. Mugosa S, Stankovic M, Turkovic N, **Sahman – Zaimovic M,** Besovic Z,Drljevic M. Pharmacovigilance: empowering healthcare professionals.Hospital Pharmacology. 2015; in press
13. B. Kucevic, M. Rolevski, **M. Sahman-Zaimovic,** Z. Besovic, S. Mugosa.Promoting public awareness of clinical trials in Montenegro. Clinical Therapeutics, 2015; 37 (8):e39
14. 13. Mugosa, Todorovic Z, **Sahman-Zaimovic**, Radosavljevic I, Bukumiric Z,Djordjevic N. Factors affecting the development of adverse drug reactions of beta blockers. Clinical Therapeutics, 2015; 37 (8):e37
15. Mugosa S, Todorovic Z, **Sahman-Zaimovic M,** Drljevic M, Djordjevic N.CYP2D6 polymorphism – risk factor for developing adverse drug reactions of beta blockers. Drugi kongres farmaceuta Crne Gore sa
međunarodnim učešćem (zbornik radova), p 157
16. 15. Sarkinovic E, Besovic Z, Drljevic M, **Sahman-Zaimovic M**, Mugosa S.Biosimilars: regulatory overview. Drugi kongres farmaceuta Crne Goresa međunarodnim učešćem (zbornik radova), p 180

Sažeci:

1. Tomic Z, Sabo A, Vukmirovic S, Milijasevic B, **Sahman M**, Golocorbin KS, Mikov M. Outhospital Drug Consumption In Montenegro In 2007. ISPOR 11th Annual European Congress, Athens, Greece, 2008. Value in Health, 2008; 11(6), A367.
2. Vukmirovic S, Sabo A, Samojlik I, Mijatovic V, Jovic J, **Sahman M**. Dangers of self-medication. The 1st Regional Southeastern Europe Conference on Safe Communities, Safe children in safe communities. 2009, Apstract book: 68-9.

## Milijasevic B, Tomic Z, Sabo A, Golocorbin-Kon S, Vukmirovic S, Sahman M. Use of anti-infectives for systemic administration funded by Health service fund in Montenegro in 2009. First Congress of Pharmacists of Montenegro with International Participation, Becici, Montenegro, 12 – 15 May, 2011. Apstract book:85-6.

## Milijasevic B, Tomic Z, Sabo A, Mikov M, Vukmirovic S, Sahman M. Out hospital use of ATC group N drugs funded by Health service fund in Montenegro in 2009. 10th Congress of the EACPT, Budapest, Hungary, 26 – 29 June 2011. Basic & Clinical Pharmacology & Toxicology, 2011, 109 (Supp. 1):146.

## Tomic Z, Sabo A, Mikov M, Milijasevic B, Andric V, Sahman M, Duborija-Kovacevic N. Use of ACE inhibitors in Serbia compared with Montenegro in 2009: Pharmacoepidemiology and Pharmacoeconomic aspects. 10th Congress of the EACPT, Budapest, Hungary, 26 – 29 June, 2011. Basic & Clinical Pharmacology & Toxicology, 2011, 109 (Supp. 1):149.

1. Milijasevic B, Tomic Z, Sabo A, Raskovic A, **Sahman M**. Out hospital use of ATC group J drugs funded by health service fund in Montenegro in 2009. 13th Serbian Congress of Pharmacologists & 3rd Serbian Congress of Clinical Pharmacology with International Participation, Palic, Serbia, 5 – 8 October, 2011. Apstract book:258-9.

Monografije

**Majda Šahman Zaimovic,**Lidija Čizmovic,Maja Stankovic,Miloš Krivokapić, ;Potrošnja ljekova u Crnoj gori 2013-2017,2018:1-79, Agencija za ljekove i medicinska sredstva Crne Gore , ISBN 978-9940-9674-2-0